<DOC>
	<DOCNO>NCT00707161</DOCNO>
	<brief_summary>The study prospective phase II trial radiation therapy concurrent cisplatin chemotherapy treatment locally advance metastatic melanoma patient deem require radiation therapy treat physician purpose local control palliation . Eligibility criterion include pathologically confirm melanoma . Patients undergo radiation therapy ( 20 treatment 2.5 Gy total 50 Gy ) concurrent cisplatin chemotherapy .</brief_summary>
	<brief_title>Radiation Therapy Concurrent Cisplatin Chemotherapy Locally Advanced Metastatic Malignant Melanoma</brief_title>
	<detailed_description>This phase II , prospective trial design determine response rate achieve cisplatin deliver concurrent radiation therapy locally advance metastatic melanoma . Radiation therapy deliver concurrent cisplatin chemotherapy outline table 2 . Radiation therapy dose 50 Gy ( 2.5 Gy per day , 5 day per week , 20 treatment ) . Cisplatin dose 100 mg/m2 give i.v . every 3 week total 2 dos ( day 1 22 ) radiation . Surgical resection residual ( recurrent ) melanoma cure palliation may perform follow chemoradiation deem appropriate treating physician ( surgical resection may plan follow pre-operative chemoradiation may perform salvage due inadequate response chemoradiation relapse follow chemoradiation ) . Surgical resection perform least 4 week follow chemoradiation ( unless deem emergent treat physician ) . If patient 's tumor inadequate response chemoradiation salvage therapy use deemed appropriate treating physician . In order allow adequate response radiation therapy , salvage therapy utilize least 4 week follow chemoradiation unless deem emergent treat physician .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : Signed studyspecific consent form prior registration . Pathologically confirm malignant melanoma . Measurable melanoma lesion deem require radiation treat physician purpose local control palliation . The lesion may primary melanoma , nodal metastasis , distant metastasis . Recurrent lesion allow . Lesion measurable clinically radiographically 2 dimension . Karnofsky Performance Scale ( KPS ) &gt; 70 . Laboratory value White blood cell ( WBC ) &gt; 3000/mm3 Absolute granulocyte count &gt; 1,500 Platelets &gt; 100,000/mm3 Total bilirubin &lt; 2.0 x institutional upper limit normal AST ALT ( aminotransferase/alanine aminotransferase ) &lt; 2.5 x institutional upper limit normal Serum calcium &lt; 1.3 x institutional upper limit normal Serum creatinine &lt; 1.5 mg/dL Creatinine clearance &gt; 50 cc/min , calculate follow : CCr = 0.85 x ( 140age ) x ( weight kg ) 72 x serum creatinine mg/dL Exclusion criterion : Systemic therapy malignant melanoma within one month precede trial enrollment . Prior irradiation plan field . Concomitant chemotherapy ( addition cisplatin ) biologic therapy allow . Significant infection coexistent medical condition would prevent use full dose chemotherapy . Preexisting sensory neuropathy ( CTC 3.0 â‰¥ Grade II ) Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>